Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Oscar Lambret
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital, Caen
National Cancer Institute (NCI)
Boehringer Ingelheim
Washington University School of Medicine
OHSU Knight Cancer Institute
University of Southern California
Seagen Inc.
Genmab
Allist Pharmaceuticals, Inc.
SONIRE Therapeutics Inc.
Servier
Fudan University
Eastern Cooperative Oncology Group
Seagen Inc.
Massachusetts General Hospital
Ono Pharmaceutical Co. Ltd
Eli Lilly and Company
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Astellas Pharma Inc
University Health Network, Toronto
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
National Institutes of Health Clinical Center (CC)
Rigshospitalet, Denmark